SCHEMBL727020

SCHEMBL727020

COc1cc(N)c(Cl)cc1C(=O)NCC1CCN(CCCn2cnnn2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HTR4 Q13639 16/20 1.00
DRD2 P14416 2/20 0.58
DRD4 P21917 2/20 0.58
DRD3 P35462 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL725773 0.99 HTR4 (0.98) HTR4DRD2DRD4DRD3
Da-6886 SCHEMBL726214 0.88 HTR4 (1.00) HTR4DRD2DRD4DRD3
Da-6886 SCHEMBL725324 0.88 HTR4 (0.98) HTR4DRD2DRD4DRD3
SCHEMBL506210 0.87 HTR4 (0.78) HTR4DRD2DRD4DRD3
SCHEMBL724942 0.87 HTR4 (1.00) HTR4DRD2DRD4DRD3
SCHEMBL724283 0.86 HTR4 (1.00) HTR4DRD2DRD4DRD3
Hydrochloric Acid SCHEMBL725813 0.85 HTR4 (0.98) HTR4DRD2DRD4DRD3
SCHEMBL7389964 0.85 HTR4 (0.78) HTR4DRD2DRD4DRD3
SCHEMBL725807 0.84 HTR4 (1.00) HTR4DRD2DRD4DRD3
SCHEMBL7389801 0.84 HTR4 (0.77) HTR4DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560955-B1 NOVEL BENZAMIDE DERIVATIVES DONG A PHARM CO LTD (KR) 2016-06-29 EP claimed
US-9221790-B2 Benzamide derivatives DONG-A PHARM. CO., LTD. (KR) 2015-12-29 US claimed
US-20130085160-A1 NOVEL BENZAMIDE DERIVATIVES DONG-A PHARM. CO., LTD. (KR) 2013-04-04 US claimed
EP-2560955-A2 NOVEL BENZAMIDE DERIVATIVES Dong-A Pharm.Co., Ltd. (KR) 2013-02-27 EP claimed
WO-2011132901-A2 NOVEL BENZAMIDE DERIVATIVES DONG-A PHARM.CO., LTD. (KR) 2011-10-27 WO claimed
EP-2560955-B1 NOVEL BENZAMIDE DERIVATIVES DONG A PHARM CO LTD (KR) 2016-06-29 EP disclosed
US-9221790-B2 Benzamide derivatives DONG-A PHARM. CO., LTD. (KR) 2015-12-29 US disclosed
US-20130085160-A1 NOVEL BENZAMIDE DERIVATIVES DONG-A PHARM. CO., LTD. (KR) 2013-04-04 US disclosed
EP-2560955-A2 NOVEL BENZAMIDE DERIVATIVES Dong-A Pharm.Co., Ltd. (KR) 2013-02-27 EP disclosed
WO-2011132901-A2 NOVEL BENZAMIDE DERIVATIVES DONG-A PHARM.CO., LTD. (KR) 2011-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085160-A1 NOVEL BENZAMIDE DERIVATIVES HTR4, GPR4, HTR5A HTR4 1/4885DRD2 570/4885DRD4 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.